Abstract:Background Lymph node metastasis (LNM) is an important prognostic factor in endometrial cancer. Anomalous microRNAs (miRNAs) are associated with cell functions and are becoming a powerful tool to characterize malignant transformation and metastasis. The aim of this study was to construct a miRNA signature to predict LNM in endometrial endometrioid carcinoma (EEC). Method Candidate target miRNAs related to LNM in EEC were screened by three methods including differentially expressed miRNAs (DEmiRs), weighted gene co-expression network analysis (WGCNA), and decision tree algorithms. Samples were randomly divided into the training and validation cohorts. A miRNA signature was built using a logistic regression model and was evaluated by the area under the curve (AUC) of receiver operating characteristic curve (ROC) and decision curve analysis (DCA). We also conducted pathway enrichment analysis and miRNA–gene regulatory network to look for potential genes and pathways engaged in LNM progression. Survival analysis was performed, and the miRNAs were tested whether they expressed differently in another independent GEO database. Result Thirty-one candidate miRNAs were screened and a final 15-miRNA signature was constructed by logistic regression. The model showed good calibration in the training and validation cohorts, with AUC of 0.824 (95% CI, 0.739–0.912) and 0.821 (95% CI, 0.691–0.925), respectively. The DCA demonstrated the miRNA signature was clinically useful. Hub miRNAs in signature seemed to contribute to EEC progression via mitotic cell cycle, cellular protein modification process, and molecular function. MiR-34c was statistically significant in survival that a higher expression of miR-34c indicated a higher survival time. MiR-34c-3p, miR-34c-5p, and miR-34b-5p were expressed differentially in GSE75968. Conclusion The miRNA signature could work as a noninvasive method to detect LNM in EEC with a high prediction accuracy. In addition, miR-34c cluster may be a key biomarker referring LNM in endometrial cancer.

MicroRNA expression profile in serum reveals novel diagnostic biomarkers for endometrial cancer

Identification of Four Serum Micrornas from a Genome-Wide Serum Microrna Expression Profile As Potential Non-Invasive Biomarkers for Endometrioid Endometrial Cancer

Novel miRNA markers for the diagnosis and prognosis of endometrial cancer

Circulating microRNAs as a Fingerprint for Endometrial Endometrioid Adenocarcinoma

Identification of Serum Circulating MicroRNAs as Novel Diagnostic Biomarkers of Gastric Cancer

Aberrant MicroRNA Expression in Patients With Endometrial Cancer

Serum miRNA-204-5p as a potential noninvasive biomarker for the diagnosis of endometrial cancer with sentinel lymph node mapping

Serum Microrna Profiling and Breast Cancer Risk: the Use of Mir-484/191 As Endogenous Controls

Identification of a six‐miRNA panel in serum benefiting pancreatic cancer diagnosis

Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma

Serum Exosomal MicroRNAs As Potential Circulating Biomarkers for Endometriosis

Expression Profile Of Circulating Micrornas As A Promising Fingerprint For Cervical Cancer Diagnosis And Monitoringy

Serum Mirnas Panel (Mir-16-2*, Mir-195, Mir-2861, Mir-497) As Novel Non-Invasive Biomarkers for Detection of Cervical Cancer

Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases

A Panel Of Microrna Signature In Serum For Colorectal Cancer Diagnosis

Expression Profile of Micrornas in Serum: A Fingerprint for Esophageal Squamous Cell Carcinoma

Four differentially expressed exosomal miRNAs as prognostic biomarkers and therapy targets in endometrial cancer: Bioinformatic analysis

Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients

Identification of a MicroRNA Signature Associated With Lymph Node Metastasis in Endometrial Endometrioid Cancer

Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features

[Microrna Expression Signature Profile and Its Clinical Significance in Endometrioid Carcinoma].